Brigham and Women’s Hospital has launched the Preventive Genomics Clinic, a facility designed to provide comprehensive DNA sequencing, interpretation and reporting of disease-associated genes. The clinic is intended to help healthy adults and their children understand and reduce their risk of future disease, according to Brigham & Women’s, which said...

Researchers at Harvard Medical School have sequenced the genomes of a family in which multiple members had pancreatic cancer and found a mutation in a gene linked to the RAS signaling pathway that controls cell growth and death. Researchers argue that the into how RABL3 impacts the signaling pathway could lead to novel targeted therapy.

Women whose family histories include certain types of cancer, or an ancestry associated with BRCA1 or BRCA2 mutations, should be assessed for increased risk of those mutations, the U.S. Preventive Services Task Force (USPSTF) concluded in a final recommendation statement on risk assessment, genetic counseling, and genetic testing for...

Liquid biopsy test provider Biocept has announced Target Selector NGS Breast Panel, a multi-gene liquid biopsy panel specifically developed for breast cancer. The Target Selector NGS Breast Panel—which runs on Thermo Fisher Scientific’s Ion Torrent NGS platform—combines Biocept’s expertise in blood sample preservation and DNA/RNA isolation, with Thermo Fisher’s...

10x Genomics has disclosed plans to raise $100 million through an initial public offering, according to a registration statement filed with the U.S. Securities and Exchange Commission—five months after the company was among six up-and-comers recognized by Clinical OMICs as Five-Year Super Successes in Genomics and Precision Medicine. Headquartered in...

As big genomics projects take off around the world, the U.S.’s initiative has made a fast start, enrolling 175,000 participants in the All of Us Research program in its first year. That represents almost 1/5thof the total number of participants the project is aiming for. Plus, approximately 80% of...

GeneCentric Therapeutics has broadened its tool set for subtyping cancer patients by acquiring Select ImmunoGenomics. The combined company now boasts a large, integrated set of RNA-based solutions for identifying the right patients for specific oncology drugs and improving response rates, treatment durability, and ultimately patient outcomes.

The Q-State Biosciences and 2bPrecise partnership aims to achieve improved diagnostic yields and patient outcomes by using clinical tools to match patients with precise therapies based on their health attributes and genetic profile.

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2)...

The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to anti-depressants most likely to work for them based on their genetic profiles. The new coverage policy, which also includes multi-gene panel testing for antipsychotic medications,...